NeuroSense’s trial of ALS drug meets primary and secondary endpoints

NeuroSense Therapeutics has reported that the Phase IIb PARADIGM clinical trial of its drug candidate, PrimeC, in amyotrophic lateral sclerosis (ALS) patients met the primary and secondary endpoints.